Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis

doi:10.5847/wjem.j.1920-8642.2021.03.012

世界急诊医学杂志（英文） ›› 2021, Vol. 12 ›› Issue (3): 228-231.doi: 10.5847/wjem.j.1920-8642.2021.03.012

收稿日期:2019-08-09 接受日期:2020-05-20 出版日期:2021-06-01 发布日期:2021-05-31

Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis

Brad E. Schwartz¹(), Karen Keller Baker¹, Andrew J. Bleinberger², Amina Lleshi², Raul Cruz-Cano³

¹ Department of Emergency Medicine, University of Maryland Capital Region Health, UM Prince George’s Hospital Center, Cheverly 20785, USA
² Ross University School of Medicine Bridgetown, Bridgetown 11093, Barbados
³ Department of Epidemiology and Biostatistics, School of Public Health of the University of Maryland, Baltimore 21201, USA

Received:2019-08-09 Accepted:2020-05-20 Online:2021-06-01 Published:2021-05-31
Contact: Brad E. Schwartz E-mail:bschwartz@som.umaryland.edu

摘要/Abstract

. [J]. 世界急诊医学杂志（英文）, 2021, 12(3): 228-231.

Brad E. Schwartz, Karen Keller Baker, Andrew J. Bleinberger, Amina Lleshi, Raul Cruz-Cano. Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis[J]. World Journal of Emergency Medicine, 2021, 12(3): 228-231.

图/表 3

参考文献 19

1	Ballou S, Nee J, Cheng V, Petersen T, Friedlander D, Lee HN, et al. Emergency department burden of gastroparesis in the United States, 2006 to 2013. J Clin Gastroenterol. 2019; 53(2):109-13. doi: 10.1097/MCG.0000000000000972
2	Khattar N, Routsolias JC. Emergency department treatment of cannabinoid hyperemesis syndrome: a review. Am J Ther. 2018; 25(3):e357-e361. doi: 10.1097/MJT.0000000000000655
3	Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, et al. Cannabinoid hyperemesis syndrome: public health implications and a novel model treatment guideline. West J Emerg Med. 2018; 19(2):380-6. doi: 10.5811/westjem.2017.11.36368 pmid: 29560069
4	Roldan CJ, Cardenas-Turanzas M, Chathampally Y, Patel S, Cardenas-Turanzas M, Chathampally Y. Randomized controlled double-blind trial comparing haloperidol combined with conventional therapy to conventional therapy alone in patients with symptomatic gastroparesis. Acad Emerg Med. 2017; 24(11):1307-14. doi: 10.1111/acem.2017.24.issue-11
5	Farmer AD, Gallagher J, Bruckner-Holt C, Aziz O. Narcotic bowel syndrome. Lancet Gastroenterol Hepatol. 2017; 2(5):361-8. doi: 10.1016/S2468-1253(16)30217-5
6	Ramirez R, Stalcup P, Croft B, Darracq MA. Haloperidol undermining gastroparesis symptoms (HUGS) in the emergency department. Am J Emerg Med. 2017; 35(8):1118-20. doi: S0735-6757(17)30182-1 pmid: 28320545
7	Lee C, Greene SL, Wong A. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome. Clin Toxicol (Phila). 2019; 57(9):773-7. doi: 10.1080/15563650.2018.1564324
8	Cole RM, Robinson F, Harvey L, Trethowan K, Murdoch V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J Pain Symptom Manage. 2004; 9(1):48-50. doi: 10.1016/0885-3924(94)90147-3
9	Blumentrath CG, Dohrmann B, Ewald N. Cannaboid hyperemesis and the cyclic vomiting syndrome in adults: recognition, diagnosis, acute and long-term treatment. Ger Med Sci. 2017; 15(1):1-8.
10	Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2013;31(6):1003.e5-e6.
11	Robbins EL, Nagel JD. Haloperidol parenterally for treatment of vomiting and nausea from gastrointestinal disorders in a group of geriatric patients: double-blind, placebo-controlled study. J Am Geriatr Soc. 1975; 23(1):38-41. pmid: 1088951
12	U.S. Food and Drug Administration. Haldol. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/015923s082,018701s057lbl.pdf.
13	Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med. 2010; 5(4):E8-E16.
14	Büttner M, Walder B, von Elm E, Tramèr MR. Is low-dose haloperidol a useful antiemetic?: a meta-analysis of published and unpublished randomized trials. Anesthesiology. 2004; 101(6):1454-63. doi: 10.1097/00000542-200412000-00028
15	MedCalc.com. Narcotic equivalence converter. Available at http://www.medcalc.com/narcotics.html.
16	Yazbeck-Karam VG, Siddik-Sayyid SM, Barakat HB, Korjian S, Aouad MT. Haloperidol versus ondansetron for treatment of established nausea and vomiting following general anesthesia: a randomized clinical trial. Anesth Analg. 2017; 124(2):438-44. doi: 10.1213/ANE.0000000000001723
17	Hardy JR, O’Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manage. 2010; 40(1):111-6. doi: 10.1016/j.jpainsymman.2009.11.321
18	Bhandari S, Venkatesan T. Novel treatments for cyclic vomiting syndrome: beyond ondansetron and amitriptyline. Curr Treat Options Gastroenterol. 2016; 14(4):495-506. pmid: 27757817
19	Lal H, Gianutsos G, Puri SK. A comparison of narcotic analgesics with neuroleptics on behavioral measures of dopaminergic activity. Life Sci. 1975; 17(1):29-34. pmid: 238089

Parameters	n	Percentage	P-value
Total patients	24 ^a
Hospitalized during non-IV HP visit	19	79.2%	0.003
Discharged after non-IV HP visit	5	20.8%	0.003
Hospitalized during IV HP visit	8	33.3%
Discharged after IV HP visit	16	66.7%
Gastroparesis	12 ^a
Hospitalized during non-IV HP visit	10	83.3%	0.036
Discharged after non-IV HP visit	2	16.7%	0.036
Hospitalized during IV HP visit	4	33.3%
Discharged after IV HP visit	8	66.7%
Cyclical vomiting	3 ^a
Hospitalized during non-IV HP visit	3	100.0%	0.100
Hospitalized during IV HP visit	0	0	0.100
Intractable vomiting	9 ^a
Hospitalized during non-IV HP visit	6	66.7%	0.637
Discharged after non-IV HP visit	3	33.3%
Hospitalized during IV HP visit	4	44.4
Discharged after IV HP visit	5	55.6%

Groups	Antiemetic	Benzodiazepin	Opiate	Antihistamine	When haloperidol administered ^a
Non-IV HP group	23 (95.8)	8 (33.3)	19 (79.2)	7 (29.2)	Not applicable
IV HP group	23 (95.8)	8 (33.3)	10 (41.7)	10 (41.7)	2 mg

Intravenous haloperidol for the treatment of intractable vomiting, cyclical vomiting, and gastroparesis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 19

相关文章 0

编辑推荐

Metrics

本文评价